SBRT for Metastatic Clear Cell Sarcoma: A Palliative Case Report

<>

Stereotactic body radiotherapy provides a noninvasive method for treating tumors with precisely focused radiation beams from multiple angles, delivering high doses while protecting surrounding healthy tissue, according to Mayo Clinic documentation. Unlike traditional radiation therapy that administers small doses across numerous sessions, this specialized treatment uses between one and five treatments.

Understanding Stereotactic Body Radiotherapy and Technical Delivery

The procedure, which is sometimes called stereotactic ablative radiotherapy or SABR, aims to destroy tumor cells or noncancerous targets in the treated area by using high radiation doses. When applied to the brain, the technique is known as stereotactic radiosurgery, as detailed by Mayo Clinic.

Medical providers utilize different machine types to deliver the radiation. A linear accelerator, or LINAC, uses X-ray photons and represents the most common equipment in modern practice. Alternatively, proton beam therapy uses charged particles instead of X-rays, offering an option for targets situated near critical organs or in areas that previously underwent radiation, according to Mayo Clinic.

Clinical Applications and Patient Selection Criteria

Healthcare professionals recommend the technique for small, well-defined targets when surgery is not feasible or safe, or when cancer has spread to a limited number of areas, a condition referred to as oligometastatic disease, according to Mayo Clinic guidelines. Treating these limited areas helps control disease progression and relieve symptoms, while potentially delaying the need to initiate or change systemic therapies like chemotherapy or hormone therapy.

Recent European retrospective research evaluated oncological outcomes for bone metastases from breast cancer treated with stereotactic body radiotherapy. Data collected across 17 European cancer centers between 2010 and 2024 analyzed 109 patients with 147 bone metastases, according to findings published by muni.cz.

That multicenter cohort analysis demonstrated a median follow-up of 29.6 months, with treatments administered at a median prescribed dose of 35 gray in five fractions. Results showed that a mean biologically effective dose of 50 gray or greater in the gross tumor volume achieved high freedom from local recurrence rates, recording 98.1 percent at one year and 93.9 percent at three years, according to muni.cz.

Potential Risks and Side Effects

Side effects from the procedure generally depend on the specific anatomical region treated. Early side effects typically manifest during or shortly after treatment and are usually short-term, according to Mayo Clinic.

Common early reactions include extreme fatigue during the first few days, swelling at or near the site causing temporary pain increases, temporary nausea or vomiting when treating tumors near the bowel or liver, and skin irritation or dryness in the treatment zone. Rare late side effects appearing months or years later can involve weakened bones, changes in bowel or bladder habits, pulmonary alterations, nerve changes, lymphedema, or very rarely, a new cancer development, as reported by Mayo Clinic.

In the European cohort analysis of breast cancer bone metastases, adverse events remained infrequent, with fracture rates documented at 2.7 percent. Multivariable analysis from that study indicated that systemic therapy correlated with improved overall survival, while higher radiation dose metrics associated with improved progression-free survival, according to muni.cz.